KIC9

KIC9 (PF3D7_1442400) is a member of the K13 compartment in Plasmodium falciparum asexual blood stages, where it co-localizes with K13 (PMID:38039338). Its role in the compartment is functionally ambiguous: conditional mislocalization of KIC9 by knock-sideways rendered parasites resistant to artemisinin, linking it to host cell hemoglobin endocytosis at the K13 compartment (PMID:34090067), yet AlphaFold2 structural analysis found no detectable vesicle trafficking or endocytosis domains, and no endocytosis or artemisinin-resistance role was detected for KIC9 in that same study (PMID:38039338). Consistent with this, direct introduction of multiple non-synonymous KIC9 mutations into 3D7 parasites did not confer reduced artemisinin susceptibility by ring-stage survival assay (PMID:38700363). Beyond its membership in the K13 compartment, the precise molecular function of KIC9 has not been characterized in the available corpus.

1. 2021 Medium

   To ask whether K13 compartment members beyond K13 itself contribute to artemisinin resistance, conditional mislocalization tested whether removing KIC9 from the compartment altered drug susceptibility.

   Evidence knock-sideways conditional mislocalization with ring-stage survival assay in P. falciparum

   PMID:34090067

   Open questions at the time

   • result described secondhand in a review, single method and lab
   • does not define KIC9's direct molecular activity in endocytosis
   • does not establish physical partners of KIC9 within the compartment
2. 2023 Medium

   To determine whether KIC9 is mechanistically a trafficking/endocytosis component, structural prediction and functional assays tested for endocytosis domains and a resistance phenotype independent of mislocalization.

   Evidence AlphaFold2 structural comparison, ring-stage survival assay, and K13 compartment co-localization in P. falciparum

   PMID:38039338

   Open questions at the time

   • absence of predicted domains does not exclude an indirect or scaffolding role
   • co-localization does not identify direct binding partners
   • negative endocytosis result may reflect assay sensitivity
3. 2024 Medium

   To test whether KIC9 sequence variation itself drives artemisinin resistance, defined mutations were introduced genetically and drug susceptibility measured.

   Evidence selection-linked integration to generate multi-mutant parasites, ring-stage survival assay with dihydroartemisinin in P. falciparum 3D7

   PMID:38700363

   Open questions at the time

   • does not exclude a KIC9 loss-of-function contribution to resistance
   • specific mutations tested may not span functionally relevant residues
   • does not resolve why mislocalization but not mutation alters susceptibility

• The precise molecular function of KIC9 within the K13 compartment, and how its mislocalization confers resistance despite the absence of trafficking domains, remains undefined.
• no direct biochemical activity assigned to KIC9
• no validated interaction partners identified for KIC9 itself
• mechanism reconciling mislocalization phenotype with lack of domains and lack of mutation effect is unresolved